[Effect of CAF'-endocrine therapy on advanced and recurrent breast cancer].
Two cases of primary advanced breast cancer and 4 cases of recurrent breast cancer were treated with cyclophosphamide, Adriamycin and FT-207 combined with hormone therapy. Adriamycin (20 mg) was injected twice a week, and an intravenous drip infusion of cyclophosphamide 150 mg), and FT-207 (400 mg) was administered daily for 3 weeks. Oophorectomy was performed in 4 cases and combination administration of tamoxifen and calcitonin was continued. CR was achieved in one of the primary cases, PR was obtained in 4 cases but one patient with pulmonary metastasis died without showing any clinical response. All cases with bone metastasis responded well. Leucopenia, alopecia, nausea and masculinization were easily controlled. No cardiac toxicity was observed.
D000328:Adult; D000368:Aged; D000732:Androstanols / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002116:Calcitonin / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D013629:Tamoxifen / Q000008:administration & dosage*
D000732:Androstanols; D013629:Tamoxifen; D004317:Doxorubicin; D003520:Cyclophosphamide; D002116:Calcitonin; C006242:mepitiostane; D005472:Fluorouracil